Incidence and risk-factors of CHOP/R-CHOP-related cardiotoxicity in patients with aggressive non-Hodgkin's lymphoma

Journal of Clinical Pharmacy and Therapeutics

Volumn 39, Issue 2, 2014, Pages 168-174

  Limat, S ^a   Daguindau, E ^a,b   Cahn, J Y ^c   Nerich, V ^a,b   Brion, A ^a   Perrin, S ^a   Woronoff Lemsi, M C ^a,b   Deconinck, E ^a,b  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b UNIVERSITÉ DE FRANCHE COMTÉ   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

anthracyclines; cardiotoxicity; dexrazoxane; lymphoma

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RAZOXANE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CONGESTIVE HEART FAILURE; DRUG EFFECT; DRUG MEGADOSE; DRUG SAFETY; FEMALE; GROUPS BY AGE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; YOUNG ADULT;

ANTHRACYCLINES; CARDIOTOXICITY; DEXRAZOXANE; LYMPHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARDIOTONIC AGENTS; CYCLOPHOSPHAMIDE; DEXRAZOXANE; DOXORUBICIN; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDNISONE; RETROSPECTIVE STUDIES; RISK FACTORS; VINCRISTINE; YOUNG ADULT;

EID: 84895523455     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/jcpt.12124     Document Type: Article

References (35)

1. Brenner H, Gondos A, Arndt V,. Recent major progress in long-term cancer patient survival disclosed by modeled period analysis. J Clin Oncol, 2007; 25: 3274-3280.
2. Shipp M, Abeloff M, Antman K, et al,. International consensus conference on high dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphoma: report of the jury. J Clin Oncol, 1999; 17: 423-429.
3. Haioun C, Lepage E, Gisselbrecht C, et al,. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH-87 protocol-a Groupe d'Etude des Lymphomes de l'Adulte study. J Clin Oncol, 2000; 18: 3025-3030.
4. Milpied N, Deconinck E, Gaillard F, et al,. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med, 2004; 350: 1287-1295.
5. Coiffier B, Lepage E, Brière J, et al,. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med, 2002; 346: 235-242.
6. Feugier P, Van Hoof C, Seban C, et al,. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol, 2005; 23: 4117-4126.
7. Pfreundschuh M, Trümper L, Osterborg A, et al,. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mabthera International Trial (MInT) Group. Lancet Oncol, 2006; 7: 379-391.
8. Coiffier B, Thieblemont C, Van Den Neste E, et al,. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood, 2010; 116: 2040-2045.
9. Limat S, Demesmay K, Voillat L, et al,. Early cardiotoxicity of CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol, 2003; 14: 277-281.
10. Hershmann D, McBride R, Eisenberg A, et al,. Doxorubicin, cardiac risk factors and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma. J Clin Oncol, 2008; 26: 3159-3165.
11. Pugh T, Ballonoff A, Ruthsoven K, et al,. Cardiac mortality in patients with stage I and II diffuse large B-cell lymphoma treated with and without radiation: a surveillance, epidemiology, and end-results analysis. Int J Radiat Oncol Biol Phys, 2010; 76: 845-849.
12. Van Dalen EC, Caron HN, Dickinson HO, et al,. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev, 2011;(6): 1-53.
13. Hensley M, Hagerty K, Kewalramani T, et al,. American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiotherapy protectants. J Clin Oncol, 2009; 27: 127-145.
14. Harris NL, Jaffe ES, Stein H, et al,. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994; 84: 1361-1392.
15. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC, 2001.
16. Venturini M, Michelotti A, Del Mastro L, et al,. Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer. J Clin Oncol, 1996; 14: 3112-3120.
17. Swain S, Whaley F, Gerber M, et al,. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol, 1997; 15: 1318-1332.
18. Swain S, Whaley F, Gerber M, et al,. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy. J Clin Oncol, 1997; 15: 1333-1340.
19. Altena R, Perik P, van Veldhuise D, et al,. Cardiovascular toxicity caused by cancer treatment: strategies for early detection. Lancet Oncol, 2009; 10: 391-399.
20. Pinder M, Duan Z, Goodwin J, et al,. Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol, 2007; 25: 3808-3815.
21. Hecquet O, Le QH, Moullet I, et al,. Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults. J Clin Oncol, 2004; 22: 1864-1871.
22. Tebbi CK, London WB, Friedman D, et al,. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol, 2007; 25: 493-500.
23. Lipshultz SE, Lipsitz SR, Orav EJ,. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without compelling evidence. J Clin Oncol, 2007; 25: 3179. Author reply 3180.
24. Hellmann K,. Dexrazoxane-associated risk for secondary malignancies in pediatric Hodgkin's disease: a claim without evidence. J Clin Oncol, 2007; 25: 4689-4690.
25. Barry EV, Vrooman LM, Dahlberg SE, et al,. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. J Clin Oncol, 2008; 26: 1106-1111.
26. Lipshultz S, Scully R, Lipsitz S, et al,. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol, 2010; 11: 950-961.
27. Rabinovich A, Weiss D, Weissman M, et al,. Dexrazoxane does not affect treatment outcome in non-Hodgkin's lymphoma patients. Am J Hematol, 2012; 87: 830-832.
28. Vrooman L, Neuberg D, Stevenson K, et al,. The low incidence of secondary acute myelogenous leukemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer, 2011; 47: 1373-1379.
29. Aapro M, Bernard-Marty C, Brain C, et al,. Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper. Ann Oncol, 2011; 22: 257-267.
30. Kilickap S, Yavuz B, Aksoy S, et al,. Addition of rituximab does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma. Med Oncol, 2008; 25: 437-442.
31. van Dalen EC, Michiels EMC, Caron HN, et al,. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev, 2008; 2010:(4): 1-41.
32. Burton C, Smith P, Vaughan-Hudson G, et al,. Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma. Br J Haematol, 2005; 130: 536-541.
33. Björkholm M, Andersson T, Ahlbom A, et al,. CNOP (mitoxantrone) chemotherapy is inferior to CHOP (doxorubicin) in the treatment of patients with aggressive non-Hodgkin lymphoma (meta-analysis). Eur J Hematol, 2008; 80: 477-482.
34. Nakamae H, Tsumura K, Terada Y, et al,. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer, 2005; 104: 2492-2498.
35. Van Dalen E, Caron H, Kremer L,. Prevention of anthrcycline-induced cardiotoxicity in children: the evidence. Eur J Cancer, 2007; 43: 1134-1140.